Jun. 5 at 2:21 AM
$DCGO I’m back on the DocGo train and even more locked n loaded.
Two major catalysts are sitting right in front
• June 16 Annual Meeting — shareholders are voting on a proposed 1-for-5 to 1-for-10 reverse split to regain NASDAQ compliance after trading under
$1. This is more of a mechanical cleanup move than a business issue. Plus, NASDAQ can also grant an additional 180-day extension, so the reverse split isn’t necessarily the only path forward.
• Strategic Alternatives Process
management confirmed the review is still active. A company doing
$300M+ in revenue sitting around a ~
$60M market cap screams undervalued and absolutely puts buyout potential on the table from private equity or a larger healthcare player.
On top of that, DocGo keeps expanding operations, including the new mobile phlebotomy rollout in South Florida through PTI Health. If margins stabilize over the next couple quarters and the political noise fully fades, this thing has serious room for a hard rerating higher
